The Rhythm | Issue 22
Issue 22 | Week of 1 September 2026
ESC Congress 2026 is taking place in Munich this week, running from 28 to 31 August, one of the largest Hot Line weeks in the meeting's recent history. This issue covers papers first published on 28 and 29 August; papers first published on 30 and 31 August fall to next week's issue under our usual first-online rule.
Cardiology Intelligence Briefing: precision over escalation
This week's papers keep pulling on the same thread: when does more intervention stop being better care? In older adults without established cardiovascular disease, a familiar prevention drug reduced major cardiovascular events but did not extend disability-free survival, separating cardiovascular protection from the broader promise of healthier ageing.1 In multivessel STEMI, physiological assessment led to fewer non-culprit lesions being treated, yet the primary composite and complications were both lower than with angiography alone. Complete revascularisation may depend less on treating every visible stenosis than on identifying which ones matter.2
The pattern extends beyond the cath lab. A faster troponin pathway was non-inferior for 30-day safety but did not shorten emergency department stays, separating faster diagnosis from faster care.3 In atrial fibrillation at intermediate stroke risk, anticoagulation reduced adverse events, but the result rested on very few events, making the direction of benefit more convincing than its exact magnitude.4 In symptomatic non-obstructive hypertrophic cardiomyopathy, the first disease-targeted therapy to succeed in phase 3 improved symptoms and exercise capacity, but with a clear signal of reduced systolic function that prevents any simple breakthrough narrative.5
Taken together, the week argues for precision over escalation. Treating more patients, intervening on more lesions or obtaining an answer faster does not necessarily produce better care. The more useful question is who benefits enough to justify acting, and what trade-offs come with that decision. It is less dramatic than a week of unequivocal wins, but much closer to the choices clinicians actually face.
